Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1615-2573
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists ; day:21 ; month:1 ; year:2022 ; pages:1-10
Heart and vessels ; (21.1.2022), 1-10
- Urheber
-
Sakai, Takahiro
Motoki, Hirohiko
Fuchida, Aya
Takeuchi, Takahiro
Otagiri, Kyuhachi
Kanai, Masafumi
Kimura, Kazuhiro
Minamisawa, Masatoshi
Yoshie, Koji
Saigusa, Tatsuya
Ebisawa, Soichiro
Okada, Ayako
Kitabayashi, Hiroshi
Kuwahara, Koichiro
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00380-022-02027-w
- URN
-
urn:nbn:de:101:1-2022050223120253276490
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sakai, Takahiro
- Motoki, Hirohiko
- Fuchida, Aya
- Takeuchi, Takahiro
- Otagiri, Kyuhachi
- Kanai, Masafumi
- Kimura, Kazuhiro
- Minamisawa, Masatoshi
- Yoshie, Koji
- Saigusa, Tatsuya
- Ebisawa, Soichiro
- Okada, Ayako
- Kitabayashi, Hiroshi
- Kuwahara, Koichiro
- SpringerLink (Online service)
Ähnliche Objekte (12)
New Anticoagulants for Atrial Fibrillation
New Anticoagulants for Atrial Fibrillation
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis
Atrial Fibrillation, Oral Anticoagulants, and Concomitant Active Cancer: Benefits and Risks
Direct Oral Anticoagulants in Atrial Fibrillation: Practical Considerations and Remaining Issues
Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulants
Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants
Direct oral anticoagulants for oral anticoagulants-naïve Asian patients with atrial fibrillation and end-stage renal disease undergoing dialysis
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
New Anticoagulants for Atrial Fibrillation
New Anticoagulants for Atrial Fibrillation
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis
Atrial Fibrillation, Oral Anticoagulants, and Concomitant Active Cancer: Benefits and Risks
Direct Oral Anticoagulants in Atrial Fibrillation: Practical Considerations and Remaining Issues
Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulants
Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants
Direct oral anticoagulants for oral anticoagulants-naïve Asian patients with atrial fibrillation and end-stage renal disease undergoing dialysis
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
New Anticoagulants for Atrial Fibrillation
New Anticoagulants for Atrial Fibrillation
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients
Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis
Atrial Fibrillation, Oral Anticoagulants, and Concomitant Active Cancer: Benefits and Risks
Direct Oral Anticoagulants in Atrial Fibrillation: Practical Considerations and Remaining Issues
Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulants
Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants
Direct oral anticoagulants for oral anticoagulants-naïve Asian patients with atrial fibrillation and end-stage renal disease undergoing dialysis
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation